
Erythropoietin Drugs Market Share, Size, Trends, Industry Analysis Report, By Type (Biologics & Biosimilars); By Product (Erythropoietin, Darbepoetin-alfa); By Application; By Region; Segment Forecast, 2023 - 2032
Description
Erythropoietin Drugs Market Share, Size, Trends, Industry Analysis Report, By Type (Biologics & Biosimilars); By Product (Erythropoietin, Darbepoetin-alfa); By Application; By Region; Segment Forecast, 2023 - 2032
The global erythropoietin drugs market size is expected to reach USD 7.65 billion by 2032, according to a new study by Polaris Market Research. The report “Erythropoietin Drugs Market Share, Size, Trends, Industry Analysis Report, By Type (Biologics & Biosimilars); By Product (Erythropoietin, Darbepoetin-alfa); By Application; By Region; Segment Forecast, 2023 - 2032” gives a detailed insight into current market dynamics and provides analysis on future market growth.
Anemia is a major health concern globally, and Erythropoietin Drugs are the primary treatment for the condition. According to the CDC chronic kidney disease in the United States, 15% of adults in the USA, or 37 million people are estimated to have CKD. It is more common in old age population than in people aged 45-64 years (13%) and 18-44 years (7%). Moreover, the increasing demand for biosimilars, which are cheaper alternatives to branded drugs, is expected to drive the need for Erythropoietin Drugs.
Adoption of erythropoietin drugs is greater in North America compared to other regions. This is due to several factors such as the high prevalence of anemia and chronic kidney disease, the availability of advanced healthcare infrastructure, and the presence of a large number of major pharmaceutical companies in the region.
Additionally, favorable government policies and reimbursement schemes have also contributed to the widespread adoption of erythropoietin drugs in North America. For example, in the United States, Medicare provides coverage for erythropoietin therapy for patients with end-stage renal disease, which has significantly increased access to these drugs for patients in the country.
In February 2023, Jesduvroq tablets, manufactured by GSK, received approval from the U.S. Food and Drug Administration as the first oral treatment option for adults suffering from anaemia due to chronic kidney disease and who have undergone dialysis for at least four months. This approval represents a significant breakthrough in the treatment of anaemia caused by chronic kidney disease, as it offers a more convenient and easily accessible treatment option for patients who previously had to rely on injectable erythropoietin drugs.
In November 2022, the UK's National Health Service made a ground-breaking achievement by performing the first-ever transfusion of lab-grown RBCs grown from the donor cells. This scientific milestone could open up new avenues for treating people with the rare blood types.
Erythropoietin Drugs Market Report Highlights
The biologics segment dominates the market, accounting for a significant share of revenue, with popular products including Procrit, NeoRecormon, Epogin, Mircera, Aranesp, and Epogen.
The erythropoietin segment holds the largest market share in 2022. Epoetin-beta is expected to grow positively in the future due to its superiority in maintaining hemoglobin concentration in hemodialysis patients over Epoetin-alfa.
The renal diseases segment holds the largest share of the market In 2022, due to developed reimbursement policies for renal transplants and related diseases are also driving this segment.
North America dominated the market and is expected to grow at a highest CAGR over the projected period because of the presence of organizations advancing drug development, Medicare coverage for CKD patients, and FDA approval of drugs like Epogen, Aranesp, and Procrit.
The global players include Amgen, Johnson & Johnson, Roche, Pfizer, Biocon, and Teva Pharmaceutical.
Polaris Market Research has segmented the Erythropoietin Drugs market report based on type, product, application and region:
Erythropoietin Drugs, Type Outlook (Revenue, USD Billion, 2019 - 2032)
Biologics
Biosimilars
Erythropoietin Drugs, Product Outlook (Revenue, USD Billion, 2019 - 2032)
Erythropoietin
Darbepoetin-alfa
Erythropoietin Drugs, Application Outlook (Revenue, USD Billion, 2019 - 2032)
Cancer
Renal Diseases
Neurology
Others
Erythropoietin Drugs, Regional Outlook (Revenue - USD Billion, 2019 - 2032)
North America
U.S.
Canada
Europe
Germany
UK
France
Italy
Spain
Russia
Netherlands
Asia Pacific
China
India
Japan
South Korea
Indonesia
Malaysia
Latin America
Argentina
Brazil
Mexico
Middle East & Africa
UAE
Saudi Arabia
Israel
South Africa
Table of Contents
116 Pages
- 1. Introduction
- 1.1. Report Description
- 1.1.1. Objectives of the Study
- 1.1.2. Market Scope
- 1.1.3. Assumptions
- 1.2. Stakeholders
- 2. Executive Summary
- 2.1. Market Highlights
- 3. Research Methodology
- 3.1. Overview
- 3.1.1. Data Mining
- 3.2. Data Sources
- 3.2.1. Primary Sources
- 3.2.2. Secondary Sources
- 4. Global Erythropoietin Drugs Market Insights
- 4.1. Erythropoietin Drugs Market – Product Snapshot
- 4.2. Erythropoietin Drugs Market Dynamics
- 4.2.1. Drivers and Opportunities
- 4.2.1.1. Increasing incidence of chronic diseases
- 4.2.1.2. Off-label use of Erythropoiesis stimulating agents (ESAs)
- 4.2.2. Restraints and Challenges
- 4.2.2.1. Patent expiration of branded drugs
- 4.3. Porter’s Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers (Moderate)
- 4.3.2. Threats of New Entrants: (Low)
- 4.3.3. Bargaining Power of Buyers (Moderate)
- 4.3.4. Threat of Substitute (Moderate)
- 4.3.5. Rivalry among existing firms (High)
- 4.4. PESTEL Analysis
- 4.5. Erythropoietin Drugs Market Product Trends
- 4.6. Value Chain Analysis
- 4.7. COVID-19 Impact Analysis
- 5. Global Erythropoietin Drugs Market, by Type
- 5.1. Key Findings
- 5.2. Introduction
- 5.2.1. Global Erythropoietin Drugs Market, by Type, 2019-2032 (USD Billion)
- 5.3. Biologics
- 5.3.1. Global Erythropoietin Drugs Market, by Biologics, by Region, 2019-2032 (USD Billion)
- 5.4. Biosimilars
- 5.4.1. Global Erythropoietin Drugs Market, by Biosimilars, by Region, 2019-2032 (USD Billion)
- 6. Global Erythropoietin Drugs Market, by Application
- 6.1. Key Findings
- 6.2. Introduction
- 6.2.1. Global Erythropoietin Drugs Market, by Application, 2019-2032 (USD Billion)
- 6.3. Cancer
- 6.3.1. Global Erythropoietin Drugs Market, by Cancer, by Region, 2019-2032 (USD Billion)
- 6.4. Renal Diseases
- 6.4.1. Global Erythropoietin Drugs Market, by Renal Diseases, by Region, 2019-2032 (USD Billion)
- 6.5. Neurology
- 6.5.1. Global Erythropoietin Drugs Market, by Neurology, by Region, 2019-2032 (USD Billion)
- 6.6. Others
- 6.6.1. Global Erythropoietin Drugs Market, by Others, by Region, 2019-2032 (USD Billion)
- 7. Global Erythropoietin Drugs Market, by Product
- 7.1. Key Findings
- 7.2. Introduction
- 7.2.1. Global Erythropoietin Drugs Market, by Product, 2019-2032 (USD Billion)
- 7.3. Erythropoietin
- 7.3.1. Global Erythropoietin Drugs Market, by Erythropoietin, By Region, 2019-2032 (USD Billion)
- 7.4. Darbepoetin-alfa
- 7.4.1. Global Erythropoietin Drugs Market, by Darbepoetin-alfa, By Region, 2019-2032 (USD Billion)
- 8. Global Erythropoietin Drugs Market, by Geography
- 8.1. Key findings
- 8.2. Introduction
- 8.2.1. Erythropoietin Drugs Market Assessment, By Geography, 2019-2032 (USD Billion)
- 8.3. Erythropoietin Drugs Market – North America
- 8.3.1. North America: Erythropoietin Drugs Market, by Type, 2019-2032 (USD Billion)
- 8.3.2. North America: Erythropoietin Drugs Market, by Product, 2019-2032 (USD Billion)
- 8.3.3. North America: Erythropoietin Drugs Market, by Application, 2019-2032 (USD Billion)
- 8.3.4. Erythropoietin Drugs Market – U.S.
- 8.3.4.1. U.S.: Erythropoietin Drugs Market, by Type, 2019-2032 (USD Billion)
- 8.3.4.2. U.S.: Erythropoietin Drugs Market, by Product, 2019-2032 (USD Billion)
- 8.3.4.3. U.S.: Erythropoietin Drugs Market, by Application, 2019-2032 (USD Billion)
- 8.3.5. Erythropoietin Drugs Market – Canada
- 8.3.5.1. Canada: Erythropoietin Drugs Market, by Type, 2019-2032 (USD Billion)
- 8.3.5.2. Canada.: Erythropoietin Drugs Market, by Product, 2019-2032 (USD Billion)
- 8.3.5.3. Canada: Erythropoietin Drugs Market, by Application, 2019-2032 (USD Billion)
- 8.4. Erythropoietin Drugs Market – Europe
- 8.4.1. Europe: Erythropoietin Drugs Market, by Type, 2019-2032 (USD Billion)
- 8.4.2. Europe.: Erythropoietin Drugs Market, by Product, 2019-2032 (USD Billion)
- 8.4.3. Europe: Erythropoietin Drugs Market, by Application, 2019-2032 (USD Billion)
- 8.4.4. Erythropoietin Drugs Market – UK
- 8.4.4.1. UK: Erythropoietin Drugs Market, by Type, 2019-2032 (USD Billion)
- 8.4.4.2. UK.: Erythropoietin Drugs Market, by Product, 2019-2032 (USD Billion)
- 8.4.4.3. UK: Erythropoietin Drugs Market, by Application, 2019-2032 (USD Billion)
- 8.4.5. Erythropoietin Drugs Market – France
- 8.4.5.1. France: Erythropoietin Drugs Market, by Type, 2019-2032 (USD Billion)
- 8.4.5.2. France.: Erythropoietin Drugs Market, by Product, 2019-2032 (USD Billion)
- 8.4.5.3. France: Erythropoietin Drugs Market, by Application, 2019-2032 (USD Billion)
- 8.4.6. Erythropoietin Drugs Market – Germany
- 8.4.6.1. Germany: Erythropoietin Drugs Market, by Type, 2019-2032 (USD Billion)
- 8.4.6.2. Germany.: Erythropoietin Drugs Market, by Product, 2019-2032 (USD Billion)
- 8.4.6.3. Germany: Erythropoietin Drugs Market, by Application, 2019-2032 (USD Billion)
- 8.4.7. Erythropoietin Drugs Market – Italy
- 8.4.7.1. Italy: Erythropoietin Drugs Market, by Type, 2019-2032 (USD Billion)
- 8.4.7.2. Italy.: Erythropoietin Drugs Market, by Product, 2019-2032 (USD Billion)
- 8.4.7.3. Italy: Erythropoietin Drugs Market, by Application, 2019-2032 (USD Billion)
- 8.4.8. Erythropoietin Drugs Market – Spain
- 8.4.8.1. Spain: Erythropoietin Drugs Market, by Type, 2019-2032 (USD Billion)
- 8.4.8.2. Spain.: Erythropoietin Drugs Market, by Product, 2019-2032 (USD Billion)
- 8.4.8.3. Spain: Erythropoietin Drugs Market, by Application, 2019-2032 (USD Billion)
- 8.4.9. Erythropoietin Drugs Market – Netherlands
- 8.4.9.1. Netherlands: Erythropoietin Drugs Market, by Type, 2019-2032 (USD Billion)
- 8.4.9.2. Netherlands.: Erythropoietin Drugs Market, by Product, 2019-2032 (USD Billion)
- 8.4.9.3. Netherlands: Erythropoietin Drugs Market, by Application, 2019-2032 (USD Billion)
- 8.4.10. Erythropoietin Drugs Market – Russia
- 8.4.10.1. Russia: Erythropoietin Drugs Market, by Type, 2019-2032 (USD Billion)
- 8.4.10.2. Russia.: Erythropoietin Drugs Market, by Product, 2019-2032 (USD Billion)
- 8.4.10.3. Russia: Erythropoietin Drugs Market, by Application, 2019-2032 (USD Billion)
- 8.5. Erythropoietin Drugs Market – Asia Pacific
- 8.5.1. Asia Pacific: Erythropoietin Drugs Market, by Type, 2019-2032 (USD Billion)
- 8.5.2. Asia Pacific.: Erythropoietin Drugs Market, by Product, 2019-2032 (USD Billion)
- 8.5.3. Asia Pacific: Erythropoietin Drugs Market, by Application, 2019-2032 (USD Billion)
- 8.5.4. Erythropoietin Drugs Market – China
- 8.5.4.1. China: Erythropoietin Drugs Market, by Type, 2019-2032 (USD Billion)
- 8.5.4.2. China.: Erythropoietin Drugs Market, by Product, 2019-2032 (USD Billion)
- 8.5.4.3. China: Erythropoietin Drugs Market, by Application, 2019-2032 (USD Billion)
- 8.5.5. Erythropoietin Drugs Market – India
- 8.5.5.1. India: Erythropoietin Drugs Market, by Type, 2019-2032 (USD Billion)
- 8.5.5.2. India.: Erythropoietin Drugs Market, by Product, 2019-2032 (USD Billion)
- 8.5.5.3. India: Erythropoietin Drugs Market, by Application, 2019-2032 (USD Billion)
- 8.5.6. Erythropoietin Drugs Market – Malaysia
- 8.5.6.1. Malaysia: Erythropoietin Drugs Market, by Type, 2019-2032 (USD Billion)
- 8.5.6.2. Malaysia.: Erythropoietin Drugs Market, by Product, 2019-2032 (USD Billion)
- 8.5.6.3. Malaysia: Erythropoietin Drugs Market, by Application, 2019-2032 (USD Billion)
- 8.5.7. Erythropoietin Drugs Market – Japan
- 8.5.7.1. Japan: Erythropoietin Drugs Market, by Type, 2019-2032 (USD Billion)
- 8.5.7.2. Japan.: Erythropoietin Drugs Market, by Product, 2019-2032 (USD Billion)
- 8.5.7.3. Japan: Erythropoietin Drugs Market, by Application, 2019-2032 (USD Billion)
- 8.5.8. Erythropoietin Drugs Market – Indonesia
- 8.5.8.1. Indonesia: Erythropoietin Drugs Market, by Type, 2019-2032 (USD Billion)
- 8.5.8.2. Indonesia.: Erythropoietin Drugs Market, by Product, 2019-2032 (USD Billion)
- 8.5.8.3. Indonesia: Erythropoietin Drugs Market, by Application, 2019-2032 (USD Billion)
- 8.5.9. Erythropoietin Drugs Market – South Korea
- 8.5.9.1. South Korea: Erythropoietin Drugs Market, by Type, 2019-2032 (USD Billion)
- 8.5.9.2. South Korea.: Erythropoietin Drugs Market, by Product, 2019-2032 (USD Billion)
- 8.5.9.3. South Korea: Erythropoietin Drugs Market, by Application, 2019-2032 (USD Billion)
- 8.6. Erythropoietin Drugs Market – Middle East & Africa
- 8.6.1. Middle East & Africa: Erythropoietin Drugs Market, by Type, 2019-2032 (USD Billion)
- 8.6.2. Middle East & Africa.: Erythropoietin Drugs Market, by Product, 2019-2032 (USD Billion)
- 8.6.3. Middle East & Africa: Erythropoietin Drugs Market, by Application, 2019-2032 (USD Billion)
- 8.6.4. Erythropoietin Drugs Market – Saudi Arabia
- 8.6.4.1. Saudi Arabia: Erythropoietin Drugs Market, by Type, 2019-2032 (USD Billion)
- 8.6.4.2. Saudi Arabia.: Erythropoietin Drugs Market, by Product, 2019-2032 (USD Billion)
- 8.6.4.3. Saudi Arabia: Erythropoietin Drugs Market, by Application, 2019-2032 (USD Billion)
- 8.6.5. Erythropoietin Drugs Market – UAE
- 8.6.5.1. UAE: Erythropoietin Drugs Market, by Type, 2019-2032 (USD Billion)
- 8.6.5.2. UAE.: Erythropoietin Drugs Market, by Product, 2019-2032 (USD Billion)
- 8.6.5.3. UAE: Erythropoietin Drugs Market, by Application, 2019-2032 (USD Billion)
- 8.6.6. Erythropoietin Drugs Market – Israel
- 8.6.6.1. Israel: Erythropoietin Drugs Market, by Type, 2019-2032 (USD Billion)
- 8.6.6.2. Israel.: Erythropoietin Drugs Market, by Product, 2019-2032 (USD Billion)
- 8.6.6.3. Israel: Erythropoietin Drugs Market, by Application, 2019-2032 (USD Billion)
- 8.6.7. Erythropoietin Drugs Market – South Africa
- 8.6.7.1. South Africa: Erythropoietin Drugs Market, by Type, 2019-2032 (USD Billion)
- 8.6.7.2. South Africa.: Erythropoietin Drugs Market, by Product, 2019-2032 (USD Billion)
- 8.6.7.3. South Africa: Erythropoietin Drugs Market, by Application, 2019-2032 (USD Billion)
- 8.7. Erythropoietin Drugs Market – Latin America
- 8.7.1. Latin America: Erythropoietin Drugs Market, by Type, 2019-2032 (USD Billion)
- 8.7.2. Latin America.: Erythropoietin Drugs Market, by Product, 2019-2032 (USD Billion)
- 8.7.3. Latin America: Erythropoietin Drugs Market, by Application, 2019-2032 (USD Billion)
- 8.7.4. Erythropoietin Drugs Market – Mexico
- 8.7.4.1. Mexico: Erythropoietin Drugs Market, by Type, 2019-2032 (USD Billion)
- 8.7.4.2. Mexico.: Erythropoietin Drugs Market, by Product, 2019-2032 (USD Billion)
- 8.7.4.3. Mexico: Erythropoietin Drugs Market, by Application, 2019-2032 (USD Billion)
- 8.7.5. Erythropoietin Drugs Market – Brazil
- 8.7.5.1. Brazil: Erythropoietin Drugs Market, by Type, 2019-2032 (USD Billion)
- 8.7.5.2. Brazil.: Erythropoietin Drugs Market, by Product, 2019-2032 (USD Billion)
- 8.7.5.3. Brazil: Erythropoietin Drugs Market, by Application, 2019-2032 (USD Billion)
- 8.7.6. Erythropoietin Drugs Market – Argentina
- 8.7.6.1. Argentina: Erythropoietin Drugs Market, by Type, 2019-2032 (USD Billion)
- 8.7.6.2. Argentina.: Erythropoietin Drugs Market, by Product, 2019-2032 (USD Billion)
- 8.7.6.3. Argentina: Erythropoietin Drugs Market, by Application, 2019-2032 (USD Billion)
- 9. Competitive Landscape
- 9.1. Expansion and Acquisition Analysis
- 9.1.1. Expansion
- 9.1.2. Acquisitions
- 9.2. Partnerships/Collaborations/Agreements/Exhibitions
- 10. Company Profiles
- 10.1. Amgen
- 10.1.1. Company Overview
- 10.1.2. Financial Performance
- 10.1.3. Product Benchmarking
- 10.1.4. Recent Development
- 10.2. Johnson & Johnson
- 10.2.1. Company Overview
- 10.2.2. Financial Performance
- 10.2.3. Product Benchmarking
- 10.2.4. Recent Development
- 10.3. Roche Ltd
- 10.3.1. Company Overview
- 10.3.2. Financial Performance
- 10.3.3. Product Benchmarking
- 10.3.4. Recent Development
- 10.4. Pfizer
- 10.4.1. Company Overview
- 10.4.2. Financial Performance
- 10.4.3. Product Benchmarking
- 10.4.4. Recent Development
- 10.5. Biocon
- 10.5.1. Company Overview
- 10.5.2. Financial Performance
- 10.5.3. Product Benchmarking
- 10.5.4. Recent Development
- 10.6. Teva Pharmaceutical
- 10.6.1. Company Overview
- 10.6.2. Financial Performance
- 10.6.3. Product Benchmarking
- 10.6.4. Recent Development
- 10.7. Kyowa Kirin
- 10.7.1. Company Overview
- 10.7.2. Financial Performance
- 10.7.3. Product Benchmarking
- 10.7.4. Recent Development
- 10.8. LG Life Sciences
- 10.8.1. Company Overview
- 10.8.2. Financial Performance
- 10.8.3. Product Benchmarking
- 10.8.4. Recent Development
- 10.9. AstraZeneca
- 10.9.1. Company Overview
- 10.9.2. Financial Performance
- 10.9.3. Product Benchmarking
- 10.9.4. Recent Development
- 10.10. Intas Pharmaceuticals
- 10.10.1. Company Overview
- 10.10.2. Financial Performance
- 10.10.3. Product Benchmarking
- 10.10.4. Recent Development
- 10.11. Shire
- 10.11.1. Company Overview
- 10.11.2. Financial Performance
- 10.11.3. Product Benchmarking
- 10.11.4. Recent Development
- 10.12. Sanofi
- 10.12.1. Company Overview
- 10.12.2. Financial Performance
- 10.12.3. Product Benchmarking
- 10.12.4. Recent Development
- 10.13. Novartis
- 10.13.1. Company Overview
- 10.13.2. Financial Performance
- 10.13.3. Product Benchmarking
- 10.13.4. Recent Development
- 10.14. Boehringer Ingelheim
- 10.14.1. Company Overview
- 10.14.2. Financial Performance
- 10.14.3. Product Benchmarking
- 10.14.4. Recent Development
- 10.15. Baxter International Inc.
- 10.15.1. Company Overview
- 10.15.2. Financial Performance
- 10.15.3. Product Benchmarking
- 10.15.4. Recent Development
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.